An Open-label, Single-dose, 3-Period Crossover Study to Evaluate the 2-way Interaction of Sitagliptin and Losartan in Healthy Adult Subjects
Latest Information Update: 16 Jul 2019
Price :
$35 *
At a glance
- Drugs Sitagliptin (Primary) ; Losartan
- Indications Diabetic nephropathies; Heart failure; Hypertension; Type 2 diabetes mellitus
- Focus Pharmacokinetics
- Sponsors Merck Sharp & Dohme
- 02 Aug 2012 Status changed from not yet recruiting to withdrawn prior to enrolment as reported by Australian New Zealand Clinical Trials Registry record.
- 05 Jun 2012 New trial record